Urology Times presents Case-Based Peer Perspectives. In each video, expert physicians provide insight on managing urology-based patient cases that highlight the use of novel agents in clinical practice.
January 18th 2023
Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the available treatment options and data that influence treatment selection for patients with the disease.
December 23rd 2022
Karim Chamie, MD, presents 2 cases of patients with muscle-invasive bladder cancer (MIBC), reviews the chosen treatment regimens, and details which clinical and non-clinical factors influence treatment recommendations.
December 21st 2022
Dr Brian Helfand presents two cases of men with prostate cancer and discusses the role of positron emission tomography (PET)-based imaging in management of patients with the disease.
December 16th 2022
Neal Shore, MD, FACS, presents the case of a 74-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the factors that influence treatment selection for patients with the disease.
August 9th 2022
Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer, details the available treatment regimens, and discusses clinical trial data on the use of androgen deprivation therapy combined with a treatment-intensifying agent.
July 19th 2022
Gordon A. Brown, DO, presents the case of a man with prostate cancer, reviews available treatment options, and discusses data on combination androgen deprivation therapy/apalutamide in patients with metastatic castration-sensitive prostate cancer.
May 23rd 2022
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer, reviews the potential treatment options, including PARP inhibitors, and highlights the importance of genetic testing when selecting treatment regimens.
April 21st 2022
Judd W. Moul, MD, FACS, provides insight on screening and diagnosis of prostate cancer, and comments on the use of biomarker tests to aid in risk stratification, management, and treatment.